ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Kite Pharma, Inc.

Kite Pharma, Inc. (KITE)

179.79
0.00
(0.00%)
Closed November 04 3:00PM
179.79
0.00
( 0.00% )
Pre Market: 6:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
179.79
Bid
107.00
Ask
179.99
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
179.79
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

KITE Latest News

Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”...

Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. (“Purchaser”), for all of the...

Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE PR Newswire NEW YORK, Aug. 31, 2017 NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Juan...

FDA Approves First Gene Therapy in U.S. -- Update

By Austen Hufford The Food and Drug Administration has approved the first gene therapy in the U.S., a long-heralded move for a promising method to combat cancer. The FDA said Wednesday it approved...

FDA Approves First Gene Therapy in U.S.

By Austen Hufford The Food and Drug Administration has approved the first gene therapy in the U.S., a long-heralded move for a promising new method of combating cancer. The FDA said Wednesday it...

Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc.

Harwood Feffer LLP Announces Investigation of Kite Pharma, Inc. PR Newswire NEW YORK, Aug. 29, 2017 NEW YORK, Aug. 29, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating...

What's News: Business & Finance -- WSJ

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (August 29, 2017). Gilead Sciences...

Gilead to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update

By Jonathan D. Rockoff and Denise Roland Gilead Sciences Inc. on Monday agreed to pay about $11 billion for Kite Pharma Inc., an ambitious bet on a new type of cancer therapy that is on the brink...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNOXBionomics Ltd
US$ 0.4844
(153.30%)
117.71M
ALBTAvalon GloboCare Corporation
US$ 4.21
(87.95%)
22.1M
AGFYAgrify Corporation
US$ 5.55
(76.75%)
10.91M
ZVSAZyVersa Therapeutics Inc
US$ 3.08
(69.23%)
18.57M
SPPLSIMPPLE Ltd
US$ 1.64
(38.98%)
24.77M
MQMarqeta Inc
US$ 3.90
(-34.45%)
3.75M
VRCAVerrica Parmaceuticals Inc
US$ 0.95
(-33.57%)
100.25k
EPRXEupraxia Pharmaceuticals Inc
US$ 2.65
(-23.74%)
37
HUBCWHub Cyber Security Ltd
US$ 0.0102
(-20.93%)
1.2k
CVGICommercial Vehicle Group Inc
US$ 2.51
(-18.51%)
20.71k
ELABElevai Labs Inc
US$ 0.0242
(20.40%)
182.19M
BNOXBionomics Ltd
US$ 0.4845
(153.35%)
117.72M
SPPLSIMPPLE Ltd
US$ 1.64
(38.98%)
24.77M
ALBTAvalon GloboCare Corporation
US$ 4.21
(87.95%)
22.1M
ZVSAZyVersa Therapeutics Inc
US$ 3.06
(68.13%)
18.59M

Discussion

View Full Feed
Bigtrade PT Bigtrade PT 5 minutes ago
I don't believe in this climb... it's going to fall more...
ELAB
$treet Trader $treet Trader 5 minutes ago
Good morning A$ & LD
Screech691 Screech691 5 minutes ago
love SGTM's commitment to sustainability with their living mulch product
COMMITTED TO SUSTAINABILITY
Microbe Living Mulch delivers impressive outcomes for your landscape, including enhanced aesthetic appeal and increased yields for healthier gardens. It aids in carbon sequestration, im
SGTM
02opida 02opida 6 minutes ago
VOTE America
$treet Trader $treet Trader 6 minutes ago
Good morning .0001ers
JettaR JettaR 6 minutes ago
Poor abandoned child. 
CBDW
getmoreshares getmoreshares 6 minutes ago
https://x.com/woofknight/status/1853787152342999283
Midwestrader Midwestrader 6 minutes ago
Evidently that CLOWN CAR CEO never really did DD and research on what happens with the pps after a REVERSE SPLIT. He probably thought it would drop a few cents and he'd be DUMPING away at say....0.35. 🤣 🤪

Nah...this POS CON JOB SHAM is now down 78.94% as of close yest
INND
docj docj 6 minutes ago
New SAB member:
Clinton Yam, MD, MS
Dr. Clinton Yam is an Associate Professor with dual appointments in the Departments of Breast Medical Oncology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Yam is leader of the triple-negative breast
CYDY
02opida 02opida 6 minutes ago
Good Morning America
BigBadWolf BigBadWolf 6 minutes ago
$ASIInvestors Learned long ago [yt]Wxk1cyYJe-o[/yt]
My $ I base it's use on my DD & highly recommend both the aforementioned to all
ASIINVESTO
getmoreshares getmoreshares 6 minutes ago
https://x.com/woofknight/status/1853787152342999283
StayHumble StayHumble 6 minutes ago
🚩🚩 Hearing there’s a Massive Reverse Split 🚩🚩Coming
https://i.imgflip.com/7idht1.jpg
DJT
jjjjjjjj jjjjjjjj 6 minutes ago
Good buys of 28M shares but only last minute buys will work! All short sellers have no more shares to borrow. They fake the shares by claiming settlement days. Keep doing
1. SET SELL HIGH our shares,
2. SET BUY HIGH at last minute with price limit.
Our time will come unst
MJNA
Eli's Gone Eli's Gone 7 minutes ago
sure LOL---and the Chevys weren't blocking for Byron and Bubba "thinks" something broke just before he allowed fellow Toyota driver Bell to pass him for the crucial 1 point needed....

a few peeps might pay after NASCAR goes over the radio traffic among those teams involved
SHEEPWOLF SHEEPWOLF 7 minutes ago
$ILLR AMONG PREMARKET GAINERS
#TRILLER IS READY TO TAKE OFF↗️
https://investorshub.advfn.com/uimage/uploads/2024/11/5/thfegGAINERS.png
ILLR
Mr.Wolf Mr.Wolf 7 minutes ago
oh contrar. Go to the Q3 management report and look at QoQ sales. Q2 growth was 400%, if you account for 1/3 of Q3 sales being offline the sales would have been approx: $358,000 ($236k/.66). which is 43% sales growth. People like and were buying the product. The challenge is how much customer loyalt
PSYCF
SHEEPWOLF SHEEPWOLF 7 minutes ago
$ILLR AMONG PREMARKET GAINERS
#TRILLER IS READY TO TAKE OFF↗️
https://investorshub.advfn.com/uimage/uploads/2024/11/5/thfegGAINERS.png
ILLR
docj docj 7 minutes ago
Who says they don't? We'll find out in due time. The trial does't start until early next year.
CYDY
TJG TJG 8 minutes ago
It seems there was an update on the Share Structure on Oct 23 Lets see if there are any differences and what they may be

OS is up 200 million and the unrestricted is up 20 million Held at DTC is the same

Oct 23

AFFU Security Details
Share Structur
AFFU DTC
TKS PARTY TKS PARTY 8 minutes ago
Any news at this point will be highly appreciated !!!!!!
CBRF
georgie18 georgie18 8 minutes ago
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented A
ALLO
GMH* GMH* 8 minutes ago
Link to abstract:
https://jitc.bmj.com/content/12/Suppl_3/A1718
Key take-away:

At a median follow-up of 25.6 months, the ORR (95% CI) in the EGFR-wt subgroup of interest for further studies was 64.3% (35.1%–87.2%). Median DOR in this subgroup was not reached (NR; 95% CI,
IOVA